Clinical Trial Update: Molecular Imaging of Brain Tumors Using Labeled Technetium-99m 1-Thio-D-Glucose. [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating molecular imaging of brain tumors using labeled Technetium-99m 1-thio-D-glucose has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasms

Drugs mentioned

• Technetium-99m 1-thio-D-glucose (technetium-99m 1-thio-D-glucose)

Snippet

Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences | Conditions: Brain, Neoplasms | Phase 1, Phase 2 | Status: COMPLETED